SCHEMBL2582001

SCHEMBL2582001

CN(C)C=C(C(=O)O)c1cccc(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.53
PARP1 P09874 1/20 0.47
ALDH1A1 P00352 7/20 0.46
MAPT P10636 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 2/20 0.46
MEN1 O00255 1/20 0.46
ALPG P10696 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TLR9 Q9NR96 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
TP53 P04637 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2582000 1.00 PTGS2 (0.53) PTGS2PARP1ALDH1A1MAPTL3MBTL1
SCHEMBL3831514 0.83 LMNA (0.44) PTGS2PARP1ALDH1A1MAPTL3MBTL1
SCHEMBL3831510 0.83 LMNA (0.44) PTGS2PARP1ALDH1A1MAPTL3MBTL1
SCHEMBL4765383 0.82 CA12 (0.52) PARP1ALDH1A1MAPTPOLBTP53
SCHEMBL4765381 0.82 CA12 (0.52) PARP1ALDH1A1MAPTPOLBTP53
SCHEMBL25230247 0.81 AKR1C1 (0.53) PTGS2ALDH1A1LMNAMEN1KMT2A
SCHEMBL11391873 0.81 AKR1C1 (0.53) PTGS2ALDH1A1LMNAMEN1KMT2A
SCHEMBL25274689 0.81 AKR1C1 (0.53) PTGS2ALDH1A1LMNAMEN1KMT2A
SCHEMBL11395366 0.81 POLB (0.60) PARP1ALDH1A1MAPTPOLBAKR1C3
SCHEMBL4768787 0.80 PTGS2 (0.55) PTGS2PARP1ALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048893-B2 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA SA (FR) 2011-11-01 US disclosed
US-20090170833-A1 PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AVENTIS PHARMA S.A. (FR) 2009-07-02 US disclosed
US-7524838-B2 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2009-04-28 US disclosed
US-20050165005-A1 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them AVENTIS PHARMA S.A. (FR) 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170833-A1 PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM C1R, CBR3, C3AR1 PTGS2 3870/4885PARP1 4626/4885ALDH1A1 2487/4885
US-20050165005-A1 Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them C1R, CBR3, C3AR1 PTGS2 3848/4885PARP1 4628/4885ALDH1A1 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.